BiotechTube
Home/Inhibrx Biosciences/John K. Jenkins
JK

John K. Jenkins

Board Member

Inhibrx Biosciences

Therapeutic Areas

OncologyRare DiseasesImmunology

Inhibrx Biosciences Pipeline

DrugIndicationPhase
INBRX-101Alpha-1 Antitrypsin Deficiency (AATD)Phase 2
INBRX-105PD-L1x4-1BB bispecific for solid tumorsPhase 1
INBRX-106OX40 agonist for solid tumorsPhase 1
INBRX-109DR5 agonist for solid tumorsPhase 1/2
INBRX-100Mesothelin-targeted IL-2 for solid tumorsPreclinical

Leadership Team at Inhibrx Biosciences

ML
Mark Lappe
Chief Executive Officer and Chairman of the Board
BP
Brendan P. Eckelman
Chief Scientific Officer and Co-Founder
KD
Kelly Deck
Chief Financial Officer
JO
Jonathon O. Bowers
Chief Business Officer
MG
Mikael G. Totterman
Chief Medical Officer
SM
Steven M. Kates
Senior Vice President, Technical Operations
QD
Quinn Deveraux
Vice President, Biology
DE
Douglas E. Williams
Board Member
VB
Vaughn B. Himes
Board Member
GB
G. Bradley Cole
Board Member
View full Inhibrx Biosciences profile